No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: The IRIS substudy

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 10, 2011, Pages 1966-1972

  Siguret, V ^a,b,c   Gouin Thibault, I ^a,b,d   Pautas, E ^b,e   Leizorovicz, A ^f  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d HÔTEL DIEU   (France)

^e HÔPITAL CHARLES FOIX   (France)

^f UNIVERSITÉ LYON 1   (France)

Author keywords

Anti FXa activity; Elderly; Renal impairment; Tinzaparin

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; CREATININE; HEPARIN; TINZAPARIN;

AGE; AGED; ARTICLE; BLEEDING; BLOOD ANALYSIS; BODY WEIGHT; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG ACCUMULATION; ENZYME ACTIVITY; FEMALE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; FACTOR XA; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KIDNEY DISEASES; MALE;

EID: 80052613955     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04458.x     Document Type: Article

References (27)

1. Spencer FA, Gore JM, Lessard D, Emery C, Pacifico L, Reed G, Gurwitz JH, Goldberg RJ. Venous thromboembolism in the elderly. A community-based perspective. Thromb Haemost 2008; 100: 780-8.
2. van Dongen CJJ, van den Belt AGM, Prins MH, Lensing AWA. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2002: CD001100. Update 2004: CD001100.
3. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edn). Chest 2008; 133: 141S-59S.
4. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: LMWH and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 673-84.
5. Garg AX, Papaioannou A, Ferko N, Campbell G, Clarke JA, Ray JG. Estimating the prevalence of renal insufficiency in seniors requiring long-term care. Kidney Int 2004; 65: 649-53.
6. ® in Renal Insufficiency Study (IRIS). Thromb Res 2011; 128: 27-34.
7. Mahé I, Aghassarian M, Drouet L, Bal-dit-Sollier C, Lacut K, Heilmann J-J, Mottier D, Bergmann JF. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function. Thromb Haemost 2007; 97: 581-6.
8. Siguret V, Pautas E, Février M, Wipff C, Durand-Gasselin B, Laurent M, Andreux JP, d'Urso M, Gaussem P. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 2000; 84: 800-4.
9. Pautas E, Gouin I, Bellot O, Andreux JP, Siguret V. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf 2002; 25: 725-33.
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
11. Clinical and Laboratory Standards Institute. Collection, Transport and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays, Approved Guideline (5th Edn). Wayne, PA: CLSI, 2008.
12. Gouin-Thibault I, Siguret V, Pautas E. A need for evidence-based clinical practice guidelines for the use of heparins in the elderly. Clin Interv Aging 2010; 5: 119-21.
13. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009; 43: 1064-83.
14. Harenberg J. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes. J Thromb Haemost 2004; 2: 547-50.
15. Bounameaux H, de Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J Thromb Haemost 2004; 2: 551-4.
16. Samama MM. Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment. Drugs Aging 2011; 28: 177-93.
17. Barrett JS, Gibiansky E, Hull RD, Planès A, Pentikis H, Hainer JW, Hua TA, Gastonguay M. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. Int J Clin Pharmacol Ther 2001; 39: 431-46.
18. Boneu B, de Moerloose P. How and when to monitor a patient treated with low molecular weight heparin. Semin Thromb Hemost 2001; 27: 519-22.
19. Cambus JP, Saivin S, Heilmann JJ, Caplain H, Boneu B, Houin G. The pharmacodynamics of tinzaparin in healthy volunteers. Br J Haematol 2002; 116: 649-52.
20. Schmid P, Brodmann D, Odermatt Y, Fischer AG, Wuillemin WA. Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. J Thromb Haemost 2009; 7: 1629-32.
21. Becker RC, Spencer FA, Gibson M, Rush JE, Sanderink G, Murphy SA, Ball SP, Antman EM; TIMI 11A Investigators. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 2002; 143: 753-9.
22. Chow SL, Zammit K, West K, Dannenhoffer M, Lopez-Candales A. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 2003; 43: 586-90.
23. Leri F, Voyce SJ, Scialla S, Glavich W, Dzielak E, Smego RA Jr, Guzek J. Enoxaparin dosing in the elderly using adjusted body weight. J Thromb Thrombolysis 2009; 28: 348-53.
24. Mismetti P, Laporte Simitsidis S, Navarro C, Sie P, d'Azemar P, Necciari J, Duret JP, Gaud C, Decousus H, Boneu B. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost 1998; 79: 1162-5.
25. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 2002; 162: 2605-9.
26. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997; 29: 1474-82.
27. Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004; 110: 392-8.